ValuEngine lowered shares of Genetic Technologies (NASDAQ:GENE) from a buy rating to a hold rating in a research report report published on Monday, ValuEngine reports.
GENE stock opened at $1.05 on Monday. Genetic Technologies has a 12-month low of $0.51 and a 12-month high of $2.04.
A hedge fund recently bought a new stake in Genetic Technologies stock. Alpine Group USVI LLC bought a new position in Genetic Technologies Limited (NASDAQ:GENE) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 28,437 shares of the biotechnology company’s stock, valued at approximately $25,000. Genetic Technologies comprises 0.1% of Alpine Group USVI LLC’s portfolio, making the stock its 15th largest holding. Alpine Group USVI LLC owned about 0.18% of Genetic Technologies at the end of the most recent quarter. Institutional investors own 3.87% of the company’s stock.
About Genetic Technologies
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage the women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer.
Featured Story: Cost of Equity
To view ValuEngine’s full report, visit ValuEngine’s official website.